Your browser doesn't support javascript.
loading
Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study.
Loke, Justin; Labopin, Myriam; Craddock, Charles; Socié, Gérard; Gedde-Dahl, Tobias; Blaise, Didier; Forcade, Edouard; Salmenniemi, Urpu; Huynh, Anne; Versluis, Jurjen; Yakoub-Agha, Ibrahim; Labussière-Wallet, Hélène; Maertens, Johan; Passweg, Jakob; Bulabois, Claude Eric; Gabellier, Ludovic; Mielke, Stephan; Castilla-Llorente, Cristina; Deconinck, Eric; Brissot, Eolia; Nagler, Arnon; Ciceri, Fabio; Mohty, Mohamad.
Afiliación
  • Loke J; University of Birmingham, Birmingham, UK.
  • Labopin M; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Craddock C; Acute Leukaemia Working Party, Paris Study Office, European Society for Blood and Marrow Transplantation, Paris, France.
  • Socié G; Hematology Department, AP-HP, Sorbonne Universités, INSERM, Centre de Recherche Saint-Antoine (CRSA), Saint Antoine Hospital, Paris, France.
  • Gedde-Dahl T; Birmingham Centre for Cellular Therapy and Transplantation, Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.
  • Blaise D; University of Warwick, Warwick, UK.
  • Forcade E; Department of Hematology-BMT, Hopital St. Louis, Paris, France.
  • Salmenniemi U; Hematology Department, Oslo University Hospital, Rikshospitalet Clinic for Cancer Medicine, Oslo, Norway.
  • Huynh A; Programme de Transplantation & Therapie Cellulaire Centre de Recherche en Cancérologie de Marseille, Marseille, France.
  • Versluis J; CHU Bordeaux Hôpital Haut-leveque, Pessac, France.
  • Yakoub-Agha I; HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.
  • Labussière-Wallet H; CHU-Institut Universitaire du Cancer Toulouse, Oncopole, Toulouse, France.
  • Maertens J; Erasmus MC Cancer Institute University Medical Center, Rotterdam, Netherlands.
  • Passweg J; CHU de Lille, INSERM U995, Lille, France.
  • Bulabois CE; Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard, Lyon, France.
  • Gabellier L; Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.
  • Mielke S; University Hospital, Hematology, Basel, Switzerland.
  • Castilla-Llorente C; CHU Grenoble Alpes, Service d`Hématologie, Grenoble, France.
  • Deconinck E; Département d`Hématologie Clinique, CHU Lapeyronie, Montpellier, France.
  • Brissot E; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Nagler A; Department of Hematology, Gustave Roussy Cancer Campus BMT Service, Villejuif, France.
  • Ciceri F; Université de Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.
  • Mohty M; Hématologie, CHU Besançon, Besançon, France.
Cancer ; 130(15): 2642-2651, 2024 Aug 01.
Article en En | MEDLINE | ID: mdl-38581695
ABSTRACT

INTRODUCTION:

For the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission.

METHODS:

This Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)-matched unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ). Univariate and multivariate analyses were undertaken to identify the prognostic impact of one or two courses of induction to attain CR.

RESULTS:

A total of 4995 patients were included with 3839 (77%) patients attaining a CR following one course of induction chemotherapy (IND1), and 1116 patients requiring two courses (IND2) to attain CR. IND2 as compared to IND1 was a poor prognostic factor in a univariate analysis and remained so in a multivariate Cox model, resulting in an increased hazard ratio of relapse (1.38; 95% confidence interval [CI], 1.16-1.64; p = .0003) and of death (1.27; 95% CI, 1.09-1.47; p = .002). Adverse prognostic factors in a multivariate analysis of the outcomes of patients requiring IND2 included age, FLT3-ITD, adverse cytogenetics, and performance status. Pretransplant measurable residual disease retained a prognostic impact regardless of IND1 or IND2.

CONCLUSION:

Initial response to chemotherapy as determined by number of courses to attain CR, retained prognostic relevance even following SCT in CR.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inducción de Remisión / Leucemia Mieloide Aguda / Hermanos / Donante no Emparentado / Antígenos HLA Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inducción de Remisión / Leucemia Mieloide Aguda / Hermanos / Donante no Emparentado / Antígenos HLA Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido